CHOP researchers presented data, chaired sessions, and delivered special lectures at the “premier hematology event of the year,” the 55th American Society of Hematology (ASH) Annual Meeting.

One of the highlights was when Children’s Hospital hematologist Katherine A. High, MD, director of the Center for Cellular and Molecular Therapeutics (CCMT), was honored with the 2013 E. Donnall Thomas Lecture and Prize for her pioneering hemophilia research.

“Dr. High is unquestionably a leader in gene therapy and has made remarkable, groundbreaking contributions to the field, demonstrating creativity, determination, and the ability to overcome numerous obstacles,” said Janis L. Abkowitz, MD, ASH president.

In her talk at the ASH Annual Meeting, “Sailing to Ithaca: Gene Therapy’s Odyssey from Investigational Agent to Therapeutic Product,” Dr. High discussed the evolution of gene therapy.

Several leukemia-related research projects led by Children’s Hospital investigators also were featured at the meeting. Children’s Hospital’s Stephan A. Grupp, MD, PhD, presented with his colleagues on follow-up results from their investigation of the treatment acute lymphoblastic leukemia (ALL) with T cells engineered to selectively kill cancerous cells. Of the 24 pediatric and adult patients who received engineered T cells, 18 had ongoing complete responses at a median of 2.6 months after treatment.

CHOP’s strong showing at the ASH meeting also included these prominent researchers:

Held Dec. 7-10 in New Orleans, the ASH conference brought together approximately 20,000 researchers, clinicians, and industry representatives.